| 1 |
**comment**- imp inhalation solution identical to ventavis inhalation solution, but imp is in a different volume presentation. please see covering letter. |
- |
- |
- |
- |
086 [1] 86 💬 |
| 2 |
0.5 mg budesonide effervescent tablet for orodispersible use |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 3 |
1 mg budesonide effervescent tablet for orodispersible use |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 4 |
120 mg sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
086 [1] 86 💬 |
| 5 |
15 mg sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
086 [1] 86 💬 |
| 6 |
1mg budesonide effervescent tablet for orodispersible use |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 7 |
25% mtd sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
086 [1] 86 💬 |
| 8 |
2mg budesonide effervescent tablet for orodispersible use |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 9 |
4.2% nacl/inhalation solution |
- |
- |
- |
- |
299 [1] 299 💬 |
| 10 |
45 mg sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
086 [1] 86 💬 |
| 11 |
90 mg sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
086 [1] 86 💬 |
| 12 |
Air001 (sodium nitrite inhalation solution) |
Nitrite |
- |
- |
- |
086 [1] 86 💬 |
| 13 |
Air001 inhalation solution |
- |
- |
- |
- |
086 [1] 86 💬 |
| 14 |
Air001 inhalation solution (expansion arm) |
- |
- |
- |
- |
086 [1] 86 💬 |
| 15 |
Amiloride solution for inhalation |
Amiloride |
[2] D00649 D00649, D07447 D07447 💬 |
SCNN1A [3] SCNN1A, SCNN1B, SCNN1G 💬 |
Aldosterone-regulated sodium reabsorption [2] Aldosterone-regulated sodium reabsorption, Taste transduction |
299 [1] 299 💬 |
| 16 |
Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed |
Apomorphine |
[2] D02004 D02004, D07460 D07460 💬 |
DRD1 [2] DRD1, DRD2 💬 |
Alcoholism [11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
| 17 |
Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed |
Apomorphine |
[2] D02004 D02004, D07460 D07460 💬 |
DRD1 [2] DRD1, DRD2 💬 |
Alcoholism [11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
| 18 |
Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed |
Apomorphine |
[2] D02004 D02004, D07460 D07460 💬 |
DRD1 [2] DRD1, DRD2 💬 |
Alcoholism [11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
| 19 |
Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed |
Apomorphine |
[2] D02004 D02004, D07460 D07460 💬 |
DRD1 [2] DRD1, DRD2 💬 |
Alcoholism [11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
| 20 |
Azd5634 for inhalation |
- |
- |
- |
- |
299 [1] 299 💬 |
| 21 |
Aztreonam for inhalation (ai) |
Aztreonam |
[2] D00240 D00240, D06558 D06558 💬 |
- |
- |
299 [1] 299 💬 |
| 22 |
Aztreonam for inhalation solution |
Aztreonam |
[2] D00240 D00240, D06558 D06558 💬 |
- |
- |
299 [1] 299 💬 |
| 23 |
Aztreonam for inhalation solution (azli) |
Aztreonam |
[2] D00240 D00240, D06558 D06558 💬 |
- |
- |
299 [1] 299 💬 |
| 24 |
Aztreonam lysine for inhalation |
Aztreonam |
[3] D00240 D00240, D02304 D02304, D06558 D06558 💬 |
- |
- |
299 [1] 299 💬 |
| 25 |
Aztreonam lysine for inhalation (azli) |
Aztreonam |
[3] D00240 D00240, D02304 D02304, D06558 D06558 💬 |
- |
- |
228 [1] 228 💬 |
| 26 |
Budesonide |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
066 [9] 66, 93, 94, 95, 96, 97, 98, 228, 299 💬 |
| 27 |
Budesonide ( zentacort capsules 3mg ) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
096 [1] 96 💬 |
| 28 |
Budesonide (6 mg) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 29 |
Budesonide (9 mg) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 30 |
Budesonide 0.5mg orodispersible tablet twice daily |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 31 |
Budesonide 1mg orodispersible tablet twice daily |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 32 |
Budesonide 6 mg capsules, hard (bux-pvii prototype) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 33 |
Budesonide 6 mg prolonged-release capsule, hard (bux-pvii prototype) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 34 |
Budesonide 6 mg prolonged-release capsules, hard (bux-pvii prototype) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 35 |
Budesonide 9 mg capsules, hard (bux-pv) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 36 |
Budesonide 9 mg capsules, hard (bux-pvii prototype) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 37 |
Budesonide 9 mg prolonged-release capsule, hard (bux-pvii prototype) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 38 |
Budesonide 9 mg prolonged-release capsules, hard (bux-pvii prototype) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 39 |
Budesonide [0.4mg/ml] viscous suspension |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 40 |
Budesonide mmx |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 41 |
Budesonide mmx 6 mg tablet |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 42 |
Budesonide mmx® |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 43 |
Budesonide mmx® 6 mg |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 44 |
Budesonide mmx® 9 mg |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 45 |
Budesonide oral suspension |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 46 |
Budesonide oral suspension [0.2 mg/ml] |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 47 |
Budesonide plus prevacid |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 48 |
Budesonide-formoterol single inhaler |
Budesonide |
[4] D00246 D00246, D01373 D01373, D05277 D05277, D07990 D07990 💬 |
ADRB2 [2] ADRB2, NR3C1 💬 |
Adrenergic signaling in cardiomyocytes [8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
299 [1] 299 💬 |
| 49 |
Budesonide-mmx |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 50 |
Budesonide-mmx® |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 51 |
Budesonide-mmx® 6 mg |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 52 |
Budesonide-mmx® 9 mg |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 53 |
Budesonide-mmx™ |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 54 |
Budesonide/formoterol |
Budesonide |
[4] D00246 D00246, D01373 D01373, D05277 D05277, D07990 D07990 💬 |
ADRB2 [2] ADRB2, NR3C1 💬 |
Adrenergic signaling in cardiomyocytes [8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
228 [1] 228 💬 |
| 55 |
Ceftazidime and tobramycin |
Ceftazidime |
[4] D00063 D00063, D00921 D00921, D02542 D02542, D07654 D07654 💬 |
- |
- |
299 [1] 299 💬 |
| 56 |
Ciprofloxacin (bayq3939) dry powder for inhalation |
Ciprofloxacin |
[2] D00186 D00186, D02216 D02216 💬 |
- |
- |
299 [1] 299 💬 |
| 57 |
Ciprofloxacin dispersion for inhalation |
Ciprofloxacin |
[2] D00186 D00186, D02216 D02216 💬 |
- |
- |
299 [1] 299 💬 |
| 58 |
Ciprofloxacin for inhalation |
Ciprofloxacin |
[2] D00186 D00186, D02216 D02216 💬 |
- |
- |
299 [1] 299 💬 |
| 59 |
Colimycine inhalation |
- |
- |
- |
- |
299 [1] 299 💬 |
| 60 |
Combination oral budesonide and rectal hydrocortisone |
Budesonide |
[2] D00088 D00088, D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 61 |
Cyclosporine a dry powder inhalation (drug) |
Cyclosporine |
[1] D00184 D00184 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
228 [1] 228 💬 |
| 62 |
Cyclosporine inhalation solution |
Cyclosporine |
[1] D00184 D00184 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
228 [1] 228 💬 |
| 63 |
Cyclosporine inhalation solution (cis) |
Cyclosporine |
[1] D00184 D00184 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
228 [1] 228 💬 |
| 64 |
Denufosol tetrasodium (ins37217) inhalation solution |
Denufosol |
[1] D03685 D03685 💬 |
- |
- |
299 [1] 299 💬 |
| 65 |
Denufosol tetrasodium inhalation solution |
Denufosol |
[1] D03685 D03685 💬 |
- |
- |
299 [1] 299 💬 |
| 66 |
Device: l606 inhalation system |
- |
- |
- |
- |
086 [1] 86 💬 |
| 67 |
Dry powder tobramycin |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 68 |
Formoterol/budesonide |
Budesonide |
[4] D00246 D00246, D01373 D01373, D05277 D05277, D07990 D07990 💬 |
ADRB2 [2] ADRB2, NR3C1 💬 |
Adrenergic signaling in cardiomyocytes [8] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
228 [1] 228 💬 |
| 69 |
Gm-csf inhalation therapy |
- |
- |
- |
- |
229 [1] 229 💬 |
| 70 |
Helium / oxygen mixed gas inhalation therapy |
Helium |
[2] D00003 D00003, D04420 D04420 💬 |
- |
- |
330 [1] 330 💬 |
| 71 |
Heparin 25mg inhalation powder, hard capsule |
Heparin |
[1] D07510 D07510 💬 |
SERPINC1 [1] SERPINC1 💬 |
Complement and coagulation cascades [1] Complement and coagulation cascades |
299 [1] 299 💬 |
| 72 |
High dose budesonide |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 73 |
High dose budesonide suspension |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 74 |
High dose budesonide tablet |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 75 |
High dose of budesonide |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
299 [1] 299 💬 |
| 76 |
Hyaluronic acid inhalation solution |
Hyaluronic acid |
[1] D08043 D08043 💬 |
- |
- |
231 [1] 231 💬 |
| 77 |
Iloprost inhalation solution (ventavis) |
Iloprost |
[1] D02721 D02721 💬 |
PTGIR [1] PTGIR 💬 |
Neuroactive ligand-receptor interaction [3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
085 [2] 85, 86 💬 |
| 78 |
Inhalation |
- |
- |
- |
- |
228 [1] 228 💬 |
| 79 |
Inhaled tobramycin |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 80 |
Inhaled/swallowed budesonide |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 81 |
Inomax 400ppm mol/mol inhalation gas |
- |
- |
- |
- |
085 [2] 85, 299 💬 |
| 82 |
Iv tobramycin |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 83 |
Kamada -aat for inhalation or inhaled aat (aat) |
- |
- |
- |
- |
231 [1] 231 💬 |
| 84 |
Kamada-aat for inhalation |
- |
- |
- |
- |
231 [1] 231 💬 |
| 85 |
Kamada-aat for inhalation, 160mg |
- |
- |
- |
- |
231 [1] 231 💬 |
| 86 |
Kamada-aat for inhalation, 80mg |
- |
- |
- |
- |
231 [1] 231 💬 |
| 87 |
L606 (liposomal treprostinil) inhalation solution 51ug |
Treprostinil |
[1] D06213 D06213 💬 |
PTGIR [1] PTGIR 💬 |
Neuroactive ligand-receptor interaction [3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 [1] 86 💬 |
| 88 |
Levodopa powder for inhalation |
Levodopa |
[1] D00059 D00059 💬 |
DRD1 [5] DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism [11] Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 [1] 6 💬 |
| 89 |
Liposomal amikacin for inhalation |
Amikacin |
[2] D00865 D00865, D02543 D02543 💬 |
- |
- |
299 [1] 299 💬 |
| 90 |
Liposomal amikacin for inhalation (arikayce™) using the pari investigational eflow® nebulizer. |
Amikacin |
[2] D00865 D00865, D02543 D02543 💬 |
- |
- |
299 [1] 299 💬 |
| 91 |
Low dose budesonide |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
097 [1] 97 💬 |
| 92 |
Low dose budesonide tablet |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 93 |
Mannitol inhalation powder |
Mannitol |
[1] D00062 D00062 💬 |
- |
- |
299 [1] 299 💬 |
| 94 |
Methylprednisolone or budesonide |
Budesonide |
[7] D00246 D00246, D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
096 [1] 96 💬 |
| 95 |
Mp-376 (levofloxacin solution for inhalation) |
Levofloxacin |
[2] D00588 D00588, D08120 D08120 💬 |
- |
- |
299 [1] 299 💬 |
| 96 |
Nebcin (tobramycin) |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 97 |
Nebulization tobramycin |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 98 |
Nitric oxide for inhalation |
Nitric Oxide |
[1] D00074 D00074 💬 |
- |
- |
086 [2] 86, 299 💬 |
| 99 |
Oligog cf-5/20, 17,5 mg, hartkapsel mit pulver zur inhalation |
- |
- |
- |
- |
299 [1] 299 💬 |
| 100 |
Oligog cf/20, 27,5 mg, hartkapsel mit pulver zur inhalation |
- |
- |
- |
- |
299 [1] 299 💬 |
| 101 |
Oligog cf/20, 37,5 mg, hartkapsel mit pulver zur inhalation |
- |
- |
- |
- |
299 [1] 299 💬 |
| 102 |
Oligog dry powder for inhalation |
- |
- |
- |
- |
299 [1] 299 💬 |
| 103 |
Oral budesonide |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 104 |
Oral budesonide suspension (mb-9) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 105 |
Oral budesonide suspension (obs) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 106 |
Oral viscous budesonide |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 107 |
Oral viscous budesonide (ovb) |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |
| 108 |
Other: tobramycin time of administration |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 109 |
Radiolabelled oligog cf-5/20 dry powder for inhalation (dpi) |
- |
- |
- |
- |
299 [1] 299 💬 |
| 110 |
Rt234 - vardenafil inhalation powder |
Vardenafil |
[3] D02731 D02731, D03260 D03260, D08668 D08668 💬 |
PDE5A [1] PDE5A 💬 |
Metabolic pathways [3] Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 [1] 86 💬 |
| 111 |
Saline 0.9% inhalation solution |
- |
- |
- |
- |
299 [1] 299 💬 |
| 112 |
Sodium nitrite inhalation solution |
Nitrite |
- |
- |
- |
086 [1] 86 💬 |
| 113 |
Spiriva respimat 2.5 microgram, solution for inhalation |
- |
- |
- |
- |
299 [1] 299 💬 |
| 114 |
Tiotropium respimat 1.25 microgram solution for inhalation |
Tiotropium |
- |
- |
- |
299 [1] 299 💬 |
| 115 |
Tiotropium respimat 1.25 microgram, solution for inhalation |
Tiotropium |
- |
- |
- |
299 [1] 299 💬 |
| 116 |
Tiotropium respimat 1.25 micrograms solution for inhalation |
Tiotropium |
- |
- |
- |
299 [1] 299 💬 |
| 117 |
Tip (tobramycin inhalation powder) |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 118 |
Tis (tobramycin inhalation solution) |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 119 |
Tobi (tobramycin) |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 120 |
Tobi 300 mg/5 ml, solution pour inhalation par nébuliseur |
- |
- |
- |
- |
299 [1] 299 💬 |
| 121 |
Tobi podhaler 28 mg hartkapseln mit pulver zur inhalation |
- |
- |
- |
- |
299 [1] 299 💬 |
| 122 |
Tobramycin |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 123 |
Tobramycin (gernebcin®) |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 124 |
Tobramycin / bramitob |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 125 |
Tobramycin / tobi |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 126 |
Tobramycin 100 pari |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 127 |
Tobramycin dry powder |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 128 |
Tobramycin for inhalation |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 129 |
Tobramycin inhalation powder |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 130 |
Tobramycin inhalation powder (tip) |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 131 |
Tobramycin inhalation powder tip delivered by the t-326 inhaler |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 132 |
Tobramycin inhalation solution |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 133 |
Tobramycin inhalation solution (tis) |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 134 |
Tobramycin inhalation solution using a pari lc® plus nebulizer. |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 135 |
Tobramycin injection 40mg/1ml |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 136 |
Tobramycin nebulized nasally |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 137 |
Tobramycin powder |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 138 |
Tobramycin solution for inhalation |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 139 |
Tobramycin solution for inhalation (tobi) |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 140 |
Tobramycin solution for inhalation 300 mg |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 141 |
Tobramycin steri-neb 300 mg/5 ml, inhalation solution |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 142 |
Tobramycin sulfate |
Sulfate ion |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 143 |
Treprostinil inhalation powder |
Treprostinil |
[1] D06213 D06213 💬 |
PTGIR [1] PTGIR 💬 |
Neuroactive ligand-receptor interaction [3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 [1] 86 💬 |
| 144 |
Treprostinil inhalations |
Treprostinil |
[1] D06213 D06213 💬 |
PTGIR [1] PTGIR 💬 |
Neuroactive ligand-receptor interaction [3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 [1] 86 💬 |
| 145 |
Treprostinil sodium for inhalation |
Treprostinil |
[1] D06213 D06213 💬 |
PTGIR [1] PTGIR 💬 |
Neuroactive ligand-receptor interaction [3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
085 [1] 85 💬 |
| 146 |
Treprostinil sodium solution for inhalation |
Treprostinil |
[1] D06213 D06213 💬 |
PTGIR [1] PTGIR 💬 |
Neuroactive ligand-receptor interaction [3] Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 [1] 86 💬 |
| 147 |
Tyvaso inhalation solution |
- |
- |
- |
- |
086 [1] 86 💬 |
| 148 |
Vancomycin hydrochloride inhalation powder |
Vancomycin |
[2] D00212 D00212, D00926 D00926 💬 |
- |
- |
299 [1] 299 💬 |
| 149 |
Vancomycin inhalation powder |
Vancomycin |
[2] D00212 D00212, D00926 D00926 💬 |
- |
- |
299 [1] 299 💬 |
| 150 |
Vantobra (tobramycin) |
Tobramycin |
[2] D00063 D00063, D02542 D02542 💬 |
- |
- |
299 [1] 299 💬 |
| 151 |
Viscous/swallowed budesonide |
Budesonide |
[1] D00246 D00246 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
098 [1] 98 💬 |